Development of Three Web-Based Computerized Versions of the Kiddie Schedule for Affective Disorders and Schizophrenia Child Psychiatric Diagnostic Interview: Preliminary Validity Data - 23/01/20
Abstract |
Objective |
To present initial validity data on three web-based computerized versions of the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS-COMP).
Method |
The sample for evaluating the validity of the clinician-administered KSADS-COMP included 511 youths 6–18 years of age who were participants in the Child Mind Institute Healthy Brain Network. The sample for evaluating the parent and youth self-administered versions of the KSADS-COMP included 158 youths 11-17 years of age recruited from three academic institutions.
Results |
Average administration time for completing the combined parent and youth clinician-administered KSADS-COMP was less time than previously reported for completing the paper-and-pencil K-SADS with only one informant (91.9 ± 50.1 minutes). Average administration times for the youth and parent self-administered KSADS-COMP were 50.9 ± 28.0 minutes and 63.2 ± 38.3 minutes, respectively, and youths and parents rated their experience using the web-based self-administered KSADS-COMP versions very positively. Diagnoses generated with all three KSADS-COMP versions demonstrated good convergent validity against established clinical rating scales and dimensional diagnostic-specific ratings derived from the KSADS-COMP. When parent and youth self-administered KSADS-COMP data were integrated, good to excellent concordance was also achieved between diagnoses derived using the self-administered and clinician-administered KSADS-COMP versions (area under the curve = 0.89–1.00).
Conclusion |
The three versions of the KSADS-COMP demonstrate promising psychometric properties, while offering efficiency in administration and scoring. The clinician-administered KSADS-COMP shows utility not only for research, but also for implementation in clinical practice, with self-report preinterview ratings that streamline administration. The self-administered KSADS-COMP versions have numerous potential research and clinical applications, including in large-scale epidemiological studies, in schools, in emergency departments, and in telehealth to address the critical shortage of child and adolescent mental health specialists.
Clinical trial registration information |
Computerized Screening for Comorbidity in Adolescents With Substance or Psychiatric Disorders; clinicaltrials.gov/; NCT01866956.
Le texte complet de cet article est disponible en PDF.Key words : child and adolescent psychiatric diagnoses, computerized assessment, K-SADS
Plan
| KSADS-COMP Access Information: To test a demo or obtain access to the KSADS-COMP diagnostic instruments, go to ksads-comp.com. |
|
| This work was funded by the National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA; grant R44 MH094092 to Drs. Kaufman and Kobak) and the National Institute of Mental Health (NIMH; grant MH060952 to Dr. Birmaher), with additional support provided by the Zanvyl and Isabelle Krieger Fund (Dr. Kaufman). |
|
| Dhananjay Vaidya, PhD, of Johns Hopkins School of Medicine, served as the statistical expert for this research. |
|
| The authors extend appreciation to the consultants who contributed to this instrument, including Deanna M. Barch, PhD, of Washington University; Marco Grados, MD, of Johns Hopkins School of Medicine; Daniel Hoover, PhD, of Kennedy Krieger Institute; Ellen Leibenluft, MD, of National Institute of Mental Health; Danny Pine, MD, of National Institute of Mental Health; Kenneth Sher, PhD, of University of Missouri; and Susan F. Tapert, PhD, of University of California San Diego. |
|
| Disclosure: Dr. Townsend’s spouse has received research support, acted as a consultant, and/or served on a speaker’s bureau for Aevi, Akili, Alcobra, Allergan, Amerex, American Academy of Child and Adolescent Psychiatry, American Psychiatric Press, Arbor, Bracket, Daiichi-Sankyo, Epharma Solutions, Forest, Genentech, Insys, Ironshore, KemPharm, Lundbeck, Merck, NIH, Neurim, Noven, Nuvelution, Otsuka, Patient-Centered Outcomes Research Institute, Pfizer, Physicians Postgraduate Press, Roche, Sage, Shire (a Takeda Company), Sunovion, Supernus Pharmaceuticals, Syneurx, Teva, TouchPoint, Tris, and Validus, in the past 36 months. Dr. Kobak has a proprietary financial interest in the computer-administered KSADS (KSADS-COMP, LLC). Dr. Milham has received grant funding from NIH. Dr. Birmaher has received funding from NIMH for research grants and has received royalties for book chapters. Dr. Kaufman has received grant funding from NIH, has served as a consultant for Pfizer and Otsuka Pharmaceuticals, and has a proprietary financial interest in the computer-administered KSADS (KSADS-COMP, LLC). Drs. Andreotti, and Escalera and Mss. Kearney, Alexander, Gill, Sylvester, Rice, and Deep have reported no biomedical financial interests or potential conflicts of interest. |
Vol 59 - N° 2
P. 309-325 - février 2020 Retour au numéro
Article précédent
- Saliva MicroRNA Differentiates Children With Autism From Peers With Typical and Atypical Development
- Steven D. Hicks, Randall L. Carpenter, Kayla E. Wagner, Rachel Pauley, Mark Barros, Cheryl Tierney-Aves, Sarah Barns, Cindy Dowd Greene, Frank A. Middleton
- Correction
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?